Core Viewpoint - The report from Industrial Securities highlights that China's innovative drugs possess high efficiency and low-cost development advantages, particularly in popular technology areas such as ADC, bispecific antibodies, and cell therapy, indicating a competitive edge in the industry [1] Group 1: Stock Performance - Zhaoyan New Drug reached the daily limit increase, while Tigermed, Haoyuan Medicine, and Kylin Pharmaceutical rose over 5% [1] - Other companies such as Jinkai Biotechnology, WuXi AppTec, Sunshine Nuohe, and Kanglong Chemical also experienced upward movement in their stock prices [1] Group 2: Industry Insights - The report emphasizes that the current competitive advantages in the innovative drug sector are expected to continue showcasing industry competitiveness [1]

Group 1 - The CRO concept stocks experienced a partial surge, with Lingkang Pharmaceutical (603669) hitting the daily limit up [1] - Baicheng Pharmaceutical (301096), Kangpeng Technology, Zhaoyan New Drug (603127), and Kailaiying (002821) also saw increases [1]

司股份数量为101,714股，占公司股份总数的0.02%，最高成交价为人民币79.3元/ 股，最低成交价为人民币75.5元/股，成交总金额为人民币7,997,727.28元（不含 交易费用）。回购方案实际执行与已披露的方案不存在差异，公司已按照披露的 方案完成回购。具体内容详见公司于2022年9月2日在上海证券交易所网站 （www.sse.com.cn）及公司指定信息披露媒体《上海证券报》披露的《昭衍新药 关于回购股份方案实施完成暨股份变动的公告》（公告编号：2022-076）。 证券代码：603127 证券简称：昭衍新药 公告编号：2025-025 北京昭衍新药研究中心股份有限公司 关于减少注册资本暨通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、通知债权人的原因 北京昭衍新药研究中心股份有限公司（以下简称"公司"）于2023年3月30 日召开的第四届董事会第二次会议及第四届监事会第二次会议审议通过了《关于 公司终止实施2021年A股员工持股计划的议案》，于2023年10月30日召开的第四 届董事 ...

Core Viewpoint - The Hong Kong pharmaceutical sector experienced a strong rally in the afternoon, with notable gains in several stocks, indicating positive market sentiment towards the industry [1] Company Summaries - Drugmaker Jiajian Ankang (02617.HK) surged over 75%, reflecting significant investor interest and confidence in its performance [1] - Junshi Biosciences (01877.HK) saw an increase of over 7%, contributing to the overall positive trend in the pharmaceutical sector [1] - Other companies such as BeiGene (06160.HK) and Zai Lab (06127.HK) also experienced upward movement, indicating a broader rally within the sector [1]

北京市天元律师事务所 关于北京昭衍新药研究中心股份有限公司 2024 年年度股东大会、2025 年第二次 A 股类别股东会议及 2025 年第二次 H 股类别股东会议的法律意见 京天股字（2025）第 401 号 致：北京昭衍新药研究中心股份有限公司 北京昭衍新药研究中心股份有限公司（以下简称"公司"）2024 年年度股东大 会（以下简称"本次年度股东大会"）、2025 年第二次 A 股类别股东会（以下简称 "本次 A 股类别股东会"）及 2025 年第二次 H 股类别股东会（以下简称"本次 H 股类别股东会"，与"本次年度股东大会"、"本次 A 股类别股东会"以下合称"本 次股东大会"）采取现场投票与网络投票相结合的方式召开，现场会议于 2025 年 6 月 18 日在北京市经济技术开发区瑞合西一路 7 号院会议室召开。北京市天元律师 事务所（以下简称"本所"）接受公司聘任，指派本所律师参加本次股东大会现场 会议，并根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》及《北京昭衍新 药研究中心股份有限公司章程》（以下简称"《公司 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2025-024 北京昭衍新药研究中心股份有限公司 2024年年度股东大会、2025 年第二次 A 股类别股东会议及 2025 年第二次 H 股类别股东会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 6 月 18 日 (二)股东大会召开的地点：北京市经济技术开发区瑞合西一路 7 号院会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 年年度股东大会 2024 | | | --- | --- | | 1、出席会议的股东和代理人人数 | 868 | | 股股东人数 其中：A | 867 | | 股） 境外上市外资股股东人数（H | 1 | | 2、出席会议的股东所持有表决权的股份总数（股） | 220,700,552 | | 其中：A 股股东持有股份总数 | 191,054,469 | | 股） 境外上市外资股股东持有股份总数 ...

以下文章来源于解码LP ，作者余梦莹 解码LP . 投资界（PEdaily.cn）旗下，专注募资动态 欢迎加入投资界读者群 LP阵容浮现。 作者 I 余梦莹 报道 I 投资界-解码LP 这始于一纸公告。 投资界-解码LP获悉，近日锦波生物和昭衍新药公告，公司已与招商局资本管理（北京） 有限公司、其他合伙人签署《合伙协议》，共同发起成立服务贸易创新发展引导基金二 期（有限合伙）（简称"服贸基金二期"）。 根据公告信息，服贸基金二期的认缴出资额为10 0亿元，其中财政部出资20亿元，深圳市 招服投资有限责任公司出资1 9亿元，杭州产业投资有限公司出资15亿元；上市企业锦波 生物、昭衍新药均出资1亿，占比均为1%。 进一步看，基金主要经营场所位于杭州市萧山区，存续期限最长为15年，招商局资本管 理（北京）有限公司作为基金管理人向合伙企业提供投资管理服务，同时也为执行事务 合伙人。 | 序号 | 合伙人名称 | 合伙人类别 | 实际认缴出资额 | 早报 | | --- | --- | --- | --- | --- | | | | | (万元) | | | 1 | 中华人民共和国财政部 | 有限合伙人 | 200, ...

日前，小商品城、昭衍新药等多家上市公司发布公告披露参与设立产业基金的进展。 小商品城在公告中指出：近日，公司与招商局资本管理（北京）有限公司及参与本基金的其他合伙 人共同签署了《合伙协议》，协议主要内容如下： 1、合伙目的 围绕创新服务贸易发展机制、发展数字贸易，加强与社会资本的协同配合，有效发挥 财政资金的政策引导和杠杆放大效应，带动社会资本支持服务贸易创新发展，推动数字贸易改革创 新发展，培育外贸新业态新模式，激发服务贸易发展新动能，推进贸易强国建设。 2、合伙期限 本合伙企业工商登记的合伙期限最长为十五（15）年，自《营业执照》载明的成立日 期起算。虽有前述约定，普通合伙人可根据全体合伙人的一致意见，报请商务部、财政部按程序研 究确定延长或提前终止本合伙企业的合伙期限。 3、出资方式 （1）所有合伙人之出资方式均为以人民币现金出资。 （2）全体合伙人同意，本合伙企业的各合伙人应于普通合伙人根据本合伙企业项目投资的具体资 金需求情况签发的各期缴付出资通知书分期进行缴付，每期的缴付出资由全体合伙人按实际认缴出 资比例缴付。为各期出资缴付之目的，普通合伙人将提前向各合伙人发出该期缴付出资通知书，列 明该合伙人 ...

Group 1 - The medical and pharmaceutical sector continues to perform strongly, with the Hong Kong medical ETF (159366) rising over 2% in early trading, marking a three-day increase [1] - Key stocks such as Kelaiying, Micron Medical, and Zhaoyan Pharmaceutical saw significant gains of 5.90%, 5.47%, and 4.73% respectively, contributing to a cumulative increase of 6.32% in the ETF over the past week [1] - A major policy announcement from the Central Committee and the State Council aims to improve public welfare and healthcare, including the establishment of a drug catalog adjustment mechanism and the promotion of quality healthcare resource sharing [1] Group 2 - Dongwu Securities highlights three factors that suggest 2025 will be a pivotal year for innovative drugs, including the orderly rollout of significant business development (BD) deals, expected profitability for more companies by 2026, and an improving domestic environment for innovative drugs [2] - The Chinese innovative drug market is poised for rapid growth, supported by favorable policies and international expansion, making it a highly promising sub-sector within the pharmaceutical industry [2] - The Hong Kong medical ETF (159366) focuses on unique medical segment leaders, including internet healthcare, CXO, and medical devices, and operates as a pure Hong Kong Stock Connect ETF with T+0 trading support [2]

Overview - The core point of the announcement is that Beijing Zhaoyan New Drug Research Center Co., Ltd. has approved an investment of up to 100 million RMB to participate in the establishment of the second phase of the Service Trade Innovation Development Guidance Fund, in collaboration with professional investment institutions [2][3]. Group 1: Fund Establishment - The company will invest in the Service Trade Innovation Development Guidance Fund Phase II, which aims to enhance the development of innovative service trade mechanisms and digital trade [3]. - The fund will be managed by China Merchants Capital Management (Beijing) Co., Ltd., which will act as the general partner and executive partner [2][3]. Group 2: Partnership Agreement - A partnership agreement has been signed among the company’s wholly-owned subsidiary, China Merchants Capital Management, and other partners, outlining the purpose of the partnership to leverage fiscal funds to stimulate social capital support for service trade innovation [3][4]. - The partnership has a maximum duration of 15 years, with provisions for extension or early termination based on unanimous agreement among partners [4]. Group 3: Investment Strategy - The fund will focus on private equity investments in service trade and digital trade sectors, as well as directly investing in relevant enterprises [9][10]. - Investments will be made through equity or equity-related debt instruments [10]. Group 4: Management and Fees - The fund will incur management fees, calculated based on a specified rate and the duration of the management period [8]. - An investment decision-making committee will be established to oversee investment and exit decisions [12]. Group 5: Fund Details - The fund is named the Service Trade Innovation Development Guidance Fund Phase II (tentative) and will operate as a limited partnership [15]. - The fund's operational scope includes private equity investment, investment management, asset management, and investment consulting [15].